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a b s t r a c t
Objectives: To determine the efﬁcacy of an ultrasound-guided platelet-rich plasma (PRP) injection in the
treatment of patients with proximal hamstring tendinopathy (PHT).
Design: Pilot prospective cohort study
Methods: Administration of a single PRP injection under ultrasound guidance to 29 patients with PHT
conﬁrmed on magnetic resonance imaging (MRI). Pain, function and sporting activity were measured
via the Victorian Institute of Sport Assessment-Proximal Hamstring Tendons (VISA-H) questionnaire,
administered before injection and at 8-weeks follow-up.
Results: The study sample consisted of 22 females and 7 males with a mean age of 45.2 years (95% CI
40.8–49.5). When comparing pre-injection VISA-H scores (mean: 43.90; 95% CI 37.77–50.03) with 8week post-injection VISA-H scores (mean: 51.14; 95% CI 43.39–58.88) in the total sample of patients, no
statistically signiﬁcant difference was found (p = 0.14). When performing separate analyses for patients
with mild (n = 9), moderate (n = 16) or marked (n = 4) PHT, no statistically signiﬁcant difference was found
in pre-and post-injection VISA-H scores for any of the groups (p = 0.86, p = 0.13, p = 0.28 respectively). 69%
of patients reported no change in their ability to undertake sport or other physical activity at 8-weeks
follow-up.
Conclusions: Patients with PHT receiving a PRP injection did not improve on clinical outcomes at 8-weeks
follow-up.
© 2018 Published by Elsevier Ltd on behalf of Sports Medicine Australia.

1. Introduction
Proximal hamstring tendinopathy (PHT) can cause severe dysfunction and chronic disability.1 PHT refers to an overuse injury
affecting the attachment of the hamstring tendons onto the
ischial tuberosity.2 Whilst PHT may occur in the non-athletic
population,1,3,4 it primarily affects the athletic population.5 It is
especially common in runners, including long distance runners,
sprinters and hurdlers, as well as occurring in activities involving
a change-of-direction.1,3,6 The typical clinical presentation of PHT
is deep lower gluteal pain that may radiate into the posterior thigh
and is exacerbated by sustained sitting, exercise and hamstring
stretching.7–9

夽 Institution where study was conducted: PRP Diagnostic Imaging, Ground Floor
Sheridan Building, Allianz Stadium; Moore Park Road, Moore Park, NSW, 2021,
Australia.
∗ Corresponding author.
E-mail address: gav levy@hotmail.com (G.M. Levy).

Due to the potential chronic disability experienced by patients
with PHT, identiﬁcation of appropriate treatment options for
patients with PHT is vital. Whilst several treatment options have
been suggested, few have been validated.9 Proposed non-surgical
treatment options for PHT are scarce10 and lacking in high-powered
study designs, yet have included conservative management, a corticosteroid injection, and shockwave therapy.
There is limited evidence as to the value of a platelet-rich
plasma (PRP) injection in the treatment of patients with PHT.9
The proposed mechanism of PRP is that cytokines and growth factors secreted by platelets accelerate the healing process, and this
has been suggested in both acute tendon injuries11,12 and chronic
tendinopathies.13 Whilst studies have demonstrated patients with
PHT receiving a PRP injection to improve on clinical outcomes,9,14
limitations in study design and sample size may have affected
the validity of their results. At present, the clinical indications for
administering a PRP injection for PHT are not well deﬁned, with no
previous studies exploring the relationship between PRP efﬁcacy
and pre-injection PHT severity.

https://doi.org/10.1016/j.jsams.2018.08.001
1440-2440/© 2018 Published by Elsevier Ltd on behalf of Sports Medicine Australia.
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The aim of this study is to determine whether a PRP injection is
associated with a change in pain, function and ability to undertake
sport or other physical activity at 8-weeks follow-up in patients
with different pre-injection grades of PHT severity. We hypothesised that patients with PHT receiving a PRP injection would
improve on clinical outcomes at 8-weeks follow-up, and that this
would be the case in all pre-injection grades of PHT severity.

2. Methods
A pilot prospective cohort study of patients with PHT treated
with a single ultrasound-guided PRP injection. The study protocol
was given ethical clearance by the local Human Research Ethics
Committee and all patients provided written informed consent
prior to enrolment into the study.
Patients were recruited from various sports medicine clinics
between December 2016 and November 2017. To be considered
for enrolment into the study, patients were required to have a conﬁrmed MRI diagnosis of chronic mild, moderate or marked PHT
by a certiﬁed interventional radiologist. The following MRI grading
classiﬁcation system for PHT was used: (a) Mild (minimal signal
change); (b) Moderate (intrasubstance tear or detachment ≤50% of
cross section); (c) Marked (intrasubstance tear or detachment >50%
of cross section).
Additionally, patients were required to meet the following
inclusion and exclusion criteria to be considered for enrolment;
Inclusion criteria:
(1) Male and female patients aged 20–75 years.
(2) Symptomatic for ≥3 weeks prior to PRP injection.
(3) No previous PRP injection into the affected hamstring.
(4) Cessation of analgesia at least 24 h prior to PRP injection.
(5) No corticosteroid injection into the affected hamstring during the 12 months prior to enrolment.
Exclusion criteria:
(1) Acute injury to the affected proximal hamstring or symptoms
of <3 weeks duration.
(2) Past or current history of cancer.
(3) Diabetes mellitus.
(4) Bleeding disorder.
(5) Currently on anti-coagulant or immunosuppressive treatment.
The outcome measure implemented was the Victorian Institute of Sport Assessment-Proximal Hamstring Tendons (VISA-H)
questionnaire (Supplementary Appendix A). This is an 8-item questionnaire that has been validated for assessing pain, function and
ability to undertake sport or other physical activity in patients with
PHT.15 The VISA-H questionnaire is scored out of a maximum of
100 points, with a minimum clinically signiﬁcant difference of 22
points, and a score of 100 points representing the least disability.15
Baseline data was collected via patients completing a written
VISA-H questionnaire immediately prior to receiving the PRP injection. Follow-up responses were obtained at 8-weeks post injection
via patients completing the VISA-H questionnaire in writing or over
the phone. Patients who elected to provide follow-up data over the
phone were contacted by a researcher at 8 weeks. Prior to enrolment into the study, all patients were instructed to not engage in
physiotherapy, massage, acupuncture or another form of physical
therapy. This information was collected at 8-weeks follow-up and
patients who engaged in any of the above modalities were excluded
from the ﬁnal analysis.
The treatment technique involved withdrawing 10 mL of venous
®
blood from the patient’s cubital fossa using the RegenKit BCT-3
®
(Regenlab , Le Mont-sur-Lausanne, Switzerland). This technology
removes >96% of the granulocytes and >99.7% of the red blood
cells. The specialised Regen PRP tube containing 10 mL of patient

blood was then centrifuged for 5 min at 1400 rpm resulting in 7 mL
of platelet-rich plasma. We removed 1 mL of the upper layer of
the platelet-poor supernatant, leaving 6 mL of platelet-rich plasma
with a mean platelet concentration of 910 × 109 /L (normal platelet
range 150–400 × 109 /L). Administration of the PRP injection into
the affected proximal hamstring was performed under ultrasound
guidance by a certiﬁed interventional radiologist using a 12-MHz
transducer on a Toshiba Aplio 500 ultrasound machine. Patients
were positioned in prone and sterile preparation of the skin was
performed at the level of the ischial tuberosity. Following the
administration of 4 mL of 1% Xylocaine (AstraZeneca) into the skin
and bursa with a 22-gauge spinal needle, an anaesthetic needle was
advanced into the areas of tearing or degeneration in the hamstring
enthesis, both at the conjoined tendon and semimembranosus, and
6 mL of PRP was ‘peppered’ into these areas of tearing or degeneration.
Since no previous tendinopathy studies have utilised the VISA-H
questionnaire as their outcome measure, we performed a poststudy power analysis to approximate the minimum sample size
required to attain 80% power at a 5% level of signiﬁcance for the
100-point VISA-H questionnaire. This analysis was performed using
our pre-and post-injection standard deviation (pre-injection SD:
16.838; post-injection SD: 21.283) and the validated minimum
clinically important difference of 22 points.15 Results of this analysis demonstrated a minimum of 12 patients required in the study
sample.
We ﬁrst investigated whether a PRP injection is associated with
a change in VISA-H scores at 8-weeks follow-up in the total sample
of patients regardless of pre-injection grading of PHT severity. We
then examined whether a PRP injection is associated with a change
in VISA-H scores at 8-weeks follow-up in patients with different
pre-injection grades of PHT severity. This involved performing a
separate analysis for patients with mild, moderate and marked PHT.
Finally, we conducted an analysis on question 7 of the VISA-H questionnaire to determine whether a PRP injection is associated with a
change in the ability to undertake sport or other physical activity at
8-weeks follow-up in the total sample of patients. Statistical analyses were undertaken using Kruskal–Wallis tests and paired t-tests
as appropriate, with data considered statistically signiﬁcant when
p < 0.05.

3. Results
Of the 61 patients initially assessed for eligibility, 12 patients
declined to participate, 11 patients did not meet the inclusion
and exclusion criteria, 3 patients engaged in physiotherapy and
6 patients were lost to follow-up due to failure to respond to
the 8-week post-injection VISA-H questionnaire. 29 patients were
included in the ﬁnal analysis (Fig. 1) and the study sample characteristics are shown in Table 1. One patient reported a large increase
in pain lasting for a duration of 72 h following PRP. There were no
other complications reported.
In the total sample of patients, when comparing pre-injection
VISA-H scores (mean: 43.90; 95% CI 37.77–50.03) with 8-weeks
post-injection VISA-H scores (mean: 51.14; 95% CI 43.39–58.88),
no statistically signiﬁcant difference was found (p = 0.14). Pre-and
post-injection VISA-H scores for all 29 patients are shown in Fig. 2.
When performing separate analyses for patients with mild, moderate and marked PHT, and comparing mean pre-injection and
post-injection VISA-H scores for each group, no statistically significant difference was found in any of the groups (p = 0.86, p = 0.13,
p = 0.28 respectively) (Table 2).
When analysing pre-and post-injection data for question 7 only
of the VISA-H scale, 5 patients (17.2%) reported an increased ability to undertake sport or other physical activity, 4 patients (13.8%)
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Assessed for eligibility (n=61)

Excluded (n=23)
- Declined to parƟcipate (n=12)
- Did not meet inclusion and
exclusion criteria (n=11)

Enrolment

Enrolled (n=38)

Lost to follow-up (n=6)

Treatment

8-week follow-up (n=32)

Excluded (n=3)
- Engaged in physiotherapy

Analysis (n=29)
Fig. 1. Patient eligibility, enrolment, follow-up and analysis.

Fig. 2. Pre-and post-injection VISA-H scores for all 29 patients.
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Table 1
Study sample characteristics.

Total
n (%)
Males: n (%)
Females: n (%)
Age: mean (95% CI)
Level of sport or other physical
activity pre-injection: n (%)a
Not at all
Modiﬁed training
Full training (at a lower level)
Full training (at same or
higher level)
Level of sport or other physical
activity 8-weeks
post-injection: n (%)a
Not at all
Modiﬁed training
Full training (at a lower level)
Full training (at same or
higher level)
Tendinopathy grade: n (%)
Mild
Moderate
Marked

29 (100)
7 (24.1)
22 (75.9)
45.2 (40.8; 49.5)

6 (20.7)
17 (58.6)
5 (17.2)
1 (3.4)

6 (20.7)
16 (55.2)
4 (13.8)
3 (10.3)

9 (31.0)
16 (55.2)
4 (13.8)

CI: Conﬁdence Interval; n: number of patients.
a
Level of sport or other physical activity based on question 7 of the VISA-H scale:
• Are you currently undertaking sport or other physical activity?
- Not at all
- Modiﬁed training ± modiﬁed competition
- Full training ± competition but not at the same level as when symptoms began
- Competing at the same or higher level as when symptoms began

Table 2
Pre-and post-injection VISA-H scores.

Total Sample
Mild PHT
Moderate PHT
Marked PHT

Pre-injection:
mean (95% CI)

Post-injection:
mean (95% CI)

p-Value

43.90 (37.77; 50.03)
40.67 (32.68; 48.65)
47.13 (37.15; 57.10)
38.25 (31.68; 44.82)

51.14 (43.39; 58.88)
39.56 (30.46; 48.65)
59.19 (47.54; 70.84)
45.0 (35.91; 54.09)

0.14
0.86
0.13
0.28

CI: Conﬁdence Interval; PHT: Proximal Hamstring Tendinopathy; VISA-H: Victorian
Institute of Sport Assessment-Proximal Hamstring Tendons.
Comparisons are presented for the total sample of patients and separately for
patients with either mild, moderate or marked proximal hamstring tendinopathy.

reported a decreased ability and 20 patients (69.0%) reported no
change in their ability to undertake sport or other physical activity
at 8-weeks follow-up.
4. Discussion
In this pilot prospective cohort study, we utilised the VISA-H
questionnaire as a validated tool for assessing pain, function and
ability to undertake sport or other physical activity in patients
with PHT.15 Results of our study have illustrated that patients with
PHT receiving a PRP injection did not improve on clinical outcomes
at 8-weeks follow-up. These ﬁndings were demonstrated in both
the total sample of patients and when we subdivided the analyses into patients with mild, moderate and marked PHT. However,
with results of the power analysis demonstrating a minimum of 12
patients required per group, our study was not sufﬁciently powered to detect a possible clinically signiﬁcant difference in patients
with mild or marked PHT.
Importantly, patients in our study engaged in a variety of sports
and other physical activity for recreational purposes and were not
competitive athletes. Therefore, whilst the mean age of patients in
our study was relatively high at 45.2 years, results of our study are

representative of patients involved in sport and physical activity
for recreational purposes rather than a typical athletic population.
To our knowledge, only the studies by Davenport et al.9 and
Fader et al.14 are similar to ours in their investigation of the efﬁcacy of a PRP injection in treating patients with PHT. In the study
by Davenport et al.,9 a PRP injection was demonstrated to be statistically signiﬁcant in improving function and quality of life in
patients with PHT. However, the study by Davenport et al.9 implemented a 6-month follow-up in the absence of a control group (e.g.
a saline injection) making it likely that natural recovery played
a large role in affecting their overall ﬁndings. Additionally, the
study by Davenport et al.9 excluded patients with the most severe
PHT (tendon tear of >50%) and it is plausible that these patients
would have responded differently to the PRP injection compared to
patients with less severe PHT. In the study by Fader et al.,14 a PRP
injection was associated with a statistically signiﬁcant 63% average decrease in pain scores on visual analogue scale. However, as
was the case in the study by Davenport et al.,9 the study by Fader
et al.14 also utilised a 6-month follow-up without a control group,
thereby increasing the likelihood of natural recovery signiﬁcantly
impacting on their results. Additionally, the only outcome measure
reported on in the study by Fader et al.14 was the visual analogue
scale. This is a relatively simplistic outcome measure that does not
factor into account function or sporting activity and therefore does
not provide a broad indication of the effectiveness of the PRP injection. Therefore, whilst the ﬁndings of Davenport et al.9 and Fader
et al.14 differ from our results, it is plausible that limitations in their
methodology may have contributed to this discrepancy.
There is conﬂicting evidence as to the effectiveness of a PRP
injection in the treatment of a range of chronic tendinopathies,16–18
with some studies demonstrating an improvement in clinical outcomes following PRP and other studies showing no beneﬁt. A
recent systematic review19 identiﬁed gender as an important
factor inﬂuencing the effectiveness of a PRP injection in the treatment of various tendinopathies, with females shown to experience
greater beneﬁts with PRP compared to males. Despite our study
being predominantly female, our results did not demonstrate
an improvement in clinical outcomes in patients with PHT who
received a PRP injection. However, the aforementioned systematic review19 did not incorporate studies on patients with PHT,
and it is possible that gender may play a critical role in certain
tendinopathies and not in others.
Similarly, there is differing evidence regarding the efﬁcacy of a
PRP injection in the treatment of acute tendon injuries,12,20 with
some studies illustrating a beneﬁcial outcome following PRP and
other studies demonstrating no value. For example, in achilles tendon ruptures, one study21 demonstrated both a PRP injection and
surgical repair to be more effective at improving patient functional
outcomes compared with surgical repair alone, whereas another
study20 found the combination of a PRP injection and surgical repair
to be no more effective than surgery alone.
There is debate within the literature as to whether serial PRP
injections are more efﬁcacious than a single PRP injection in the
treatment of chronic tendinopathies.12 In our study, we administered a single PRP injection as this approach was consistent with
the current literature on PRP for PHT.9,14 Whilst there is limited evidence comparing a single with multiple PRP injections
for the treatment of chronic tendinopathies, a recent systematic
review and meta-analysis22 concluded that multiple PRP injections were more effective than a single PRP injection for improving
clinical outcomes at 6-months follow-up in patients with patella
tendinopathy. Nevertheless, further evidence comparing a single
with multiple PRP injections in the treatment of a range of other
chronic tendinopathies is still required.
Whilst few treatment options have been validated for PHT,
various treatments have been suggested,9 such as conservative
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management, a corticosteroid injection and shockwave therapy.
Although not currently validated with further research, two case
reports10,23 have identiﬁed conservative management in the form
of a hamstring eccentric exercise program to be beneﬁcial in
decreasing pain in patients with PHT. The efﬁcacy of a corticosteroid injection for treating PHT is limited and conﬂicting, with one
study7 reporting a sustained reduction in pain at 2 years follow-up,
and another study8 demonstrating symptom recurrence following short-term pain relief. Despite limited evidence, studies24,25
have demonstrated shockwave therapy to be beneﬁcial in reducing
pain in patients with PHT. The effectiveness of surgery for treating PHT has only been studied retrospectively, with two studies
demonstrating return to pre-symptom level of sporting activity
following surgery.3,5 However, surgical repair is associated with a
higher risk of complications including sciatic nerve damage, infection and hamstring origin rupture, as well as longer recovery times
compared with non-surgical treatment.
There were several limitations that require consideration when
interpreting the results of our study. Firstly, the absence of a control group may have underestimated the impact of natural recovery
on our results. However, whilst natural recovery may have affected
our results at 8-weeks follow-up, it is likely that natural recovery
played an even larger role in the studies by Davenport et al.9 and
Fader et al.14 which implemented 6-month follow-ups. Secondly,
our study imposed no restrictions on the volume and intensity of
physical activity and/or sport that patients could perform in the
period between receiving the PRP injection and obtaining followup data. Similarly, a pilot study exploring the effectiveness of a
PRP injection in rotator cuff tendinopathy13 and the study by Davenport et al.9 imposed no limitations on physical activity and/or
sport in this period. Conversely, a high-powered randomised controlled trial26 exploring the efﬁcacy of a PRP injection in achilles
tendinopathy did implement restrictions. Whilst difﬁcult to quantify, it is plausible that engagement in physical activity and/or
sport in the period between receiving a PRP injection and obtaining
follow-up data may reduce the effectiveness of the PRP injection,
thereby impacting on our results. Thirdly, there is a high risk of bias
being introduced into our study due to the placebo effect. This is
especially the case since the VISA-H questionnaire is a subjective
outcome measure. It is therefore plausible that a placebo response
caused our results to be overstated in favour of the PRP injection.
Fourthly, our study did not include data pertaining to the mean
duration of symptoms experienced by patients prior to receiving
the PRP injection. With our inclusion criteria specifying patients to
have been symptomatic for ≥3 weeks prior to PRP injection, it is
possible that patients experiencing symptoms for a longer duration prior to PRP would have responded differently compared with
patients having only had symptoms for 3 weeks. Fifthly, whilst
there is no current standardised amount of PRP that should be
used, patients in our study were administered 6 mL of PRP. This
is a relatively large volume of PRP and it is therefore possible that
surrounding soft tissues may have been affected. Finally, our study
involved a relatively small sample size of 29 patients. However, our
sample size was still comparatively larger than the sample sizes
used in the studies by Davenport et al.9 and Fader et al.,14 making
our study the largest study to date exploring the efﬁcacy of a PRP
injection for PHT.

5. Conclusion
Given the paucity of evidence for the usage of a PRP injection in
the treatment of patients with PHT, we suggest that our study is an
important addition to the current literature. To our knowledge, our
study is the ﬁrst to have explored the efﬁcacy of a PRP injection in
the treatment of patients with different pre-injection grades of PHT

5

severity. Results of our study have demonstrated that patients with
PHT receiving a PRP injection did not improve on clinical outcomes,
and this was the case for all pre-injection grades of PHT severity.
Our results differ from our original hypothesis and are at variance
with other studies exploring a PRP injection for PHT.9,14 However,
these studies are limited by study design and sample size. Additionally, the evidence exploring the efﬁcacy of a PRP injection in the
treatment of various other chronic tendinopathies, such as patella
tendinopathy, remains conﬂicting throughout the literature. Since
the evidence base for the efﬁcacy of a PRP injection in the treatment of patients with PHT is limited by the number of studies, their
design and sample size, we suggest higher powered randomised
controlled trials that include varying pre-injection grades of PHT
may prove a fruitful avenue of further investigation.
Practical implications
• A platelet-rich plasma injection was not associated with a reduction in pain in patients with proximal hamstring tendinopathy.
• A platelet-rich plasma injection was not associated with an
improvement in function in patients with proximal hamstring
tendinopathy.
• Most patients with proximal hamstring tendinopathy had no
change in their ability to undertake sport or other physical activity following a platelet-rich plasma injection.
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